News Headlines Article

Health Care Digest: Attacking a deadly infant virus, Medicaid’s smoking gun and exporting genetic expertise
San Francisco Business Times

In the grand scheme of biotech fundraising, $6 million is a pittance. Just don’t tell Meissa Vaccines Inc. co-founder and CEO Marty Moore.

Moore left Emory University in Atlanta and moved west, joining co-founder and former MedImmune vaccines researcher Roderick Tang in San Carlos, to tap synthetic biology and reverse genetics to develop a longer-lasting vaccine for respiratory syncytial virus.